-transparent.png){kind=logo}
Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) has been associated with coagulation dysfunction which predisposes patients to an increased risk of both venous and arterial thromboembolism, increasing the short-term morbidity and mortality. Current data evidenced that the rate of post-discharge thrombotic events in COVID-19 patients is lower compared to that observed during hospitalization. Rather than 'true thrombotic events', these complications seem more probably 'immunothrombosis' consequent to the recent infection. Unfortunately, the absence of data from randomized controlled trials, large prospective cohorts and ambulatory COVID-19 patients, left unresolved the question regarding the need of post-discharge thromboprophylaxis due to the absence of strong-level recommendations.
M Zuin, and
G Rigatelli, and
G Zuliani, and
L Roncon
December 2020,
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery,
M Zuin, and
G Rigatelli, and
G Zuliani, and
L Roncon
January 2023,
Cureus,
M Zuin, and
G Rigatelli, and
G Zuliani, and
L Roncon
July 2021,
Clinical case reports,
M Zuin, and
G Rigatelli, and
G Zuliani, and
L Roncon
November 2020,
Clinica chimica acta; international journal of clinical chemistry,
M Zuin, and
G Rigatelli, and
G Zuliani, and
L Roncon
May 2021,
JACC. Cardiovascular interventions,
M Zuin, and
G Rigatelli, and
G Zuliani, and
L Roncon
September 2020,
Journal of surgical case reports,
M Zuin, and
G Rigatelli, and
G Zuliani, and
L Roncon
August 2020,
Thrombosis research,
M Zuin, and
G Rigatelli, and
G Zuliani, and
L Roncon
July 2021,
British journal of haematology,
M Zuin, and
G Rigatelli, and
G Zuliani, and
L Roncon
January 2020,
Therapie,
M Zuin, and
G Rigatelli, and
G Zuliani, and
L Roncon
April 2021,
BMJ (Clinical research ed.),
